Revenue remains highly volatile and milestone-dependent, with quarterly figures fluctuating between $32,000 and $19.1 million, while R&D intensity remains elevated with quarterly expenditures consistently ranging between $31 million and $44.8 million.
| Sales/Revenue | 22.57M | 22.5M | 45.56M | 14.09M | 102.69M | 0 | 0 |
| Revenue Growth % | -52.13% | -50.61% | 223.37% | -86.28% | - | - | - |
| Cost of Goods Sold | 559K | 59K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 0.26% | - | - | - | - | - |
| Gross Profit | 22.01M | 22.44M | 45.56M | 14.09M | 102.69M | 0 | 0 |
| Gross Margin % | 97.52% | 99.74% | 100% | 100% | 100% | - | - |
| Gross Profit Growth % | - | -50.74% | 223.37% | -86.28% | - | - | - |
| Operating Expenses | 237.18M | 248.13M | 221.85M | 197.06M | 106.25M | 34.98M | 6.63M |
| OpEx % of Revenue | - | 1102.64% | 486.91% | 1398.56% | 103.46% | - | - |
| Selling, General & Admin | 102.59M | 106.3M | 70.45M | 37.63M | 19.51M | 5.68M | 1.69M |
| SG&A % of Revenue | - | 472.36% | 154.61% | 267.09% | 19% | - | - |
| Research & Development | 134.59M | 141.83M | 151.41M | 159.42M | 86.74M | 28.97M | 4.94M |
| R&D % of Revenue | - | 630.28% | 332.3% | 1131.47% | 84.47% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 326K | 0 |
| Operating Income | -215.18M | -225.68M | -176.29M | -182.97M | -3.56M | -34.98M | -6.63M |
| Operating Margin % | -953.59% | -1002.9% | -386.91% | -1298.56% | -3.46% | - | - |
| Operating Income Growth % | - | -28.02% | 3.65% | -5043.86% | 89.83% | -427.39% | - |
| EBITDA | -214.95M | -225.46M | -176.18M | -182.92M | -3.55M | -34.97M | -6.63M |
| EBITDA Margin % | -952.57% | -1001.92% | -386.66% | -1298.21% | -3.45% | - | - |
| EBITDA Growth % | -13.38% | -27.98% | 3.69% | -5055.52% | 89.85% | -427.41% | - |
| D&A (Non-Cash Add-back) | 230K | 220K | 113K | 49K | 9K | 5K | 1.22K |
| EBIT | -232.04M | -242.54M | -241.6M | -176.91M | -22.35M | -41.37M | -6.63M |
| Net Interest Income | 24.28M | 27.59M | 16.88M | 3.42M | -287K | -411K | 851 |
| Interest Income | 24.28M | 27.59M | 16.88M | 10.22M | 0 | 0 | 851 |
| Interest Expense | 0 | 0 | 0 | 6.8M | 287K | 411K | 0 |
| Other Income/Expense | 2.44M | 21.86M | -65.31M | 6.06M | -19.08M | -6.81M | -390.91K |
| Pretax Income | -212.73M | -203.82M | -241.6M | -176.91M | -22.63M | -41.78M | -7.02M |
| Pretax Margin % | -942.76% | -905.74% | -530.25% | -1255.57% | -22.04% | - | - |
| Income Tax | 0 | 0 | -1K | 27K | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | -0.02% | 0% | 0% | 0% |
| Net Income | -212.73M | -203.82M | -241.6M | -176.94M | -22.63M | -41.78M | -7.02M |
| Net Margin % | -942.76% | -905.74% | -530.25% | -1255.76% | -22.04% | - | - |
| Net Income Growth % | -13.54% | 15.64% | -36.54% | -681.73% | 45.83% | -494.98% | - |
| Net Income (Continuing) | -212.73M | -203.82M | -241.6M | -176.94M | -22.63M | -41.78M | -7.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.76 | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
| EPS Growth % | 5.24% | 31.64% | -19.07% | -80.67% | 64.37% | -190.43% | - |
| EPS (Basic) | - | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
| Diluted Shares Outstanding | 121.1M | 114.4M | 94.36M | 82.16M | 18.97M | 17.75M | 17.75M |
| Basic Shares Outstanding | 121.1M | 114.4M | 94.36M | 82.16M | 18.97M | 17.75M | 17.75M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Binary clinical trial outcomes
As reported in financial statements, NAMS's revenue remains highly volatile and non-recurring, with quarterly figures fluctuating between $32,000 and $19.1 million, reflecting the milestone-driven nature of its licensing agreements rather than any underlying commercial product adoption or consistent market demand for its lead cardiovascular candidate.
The revenue trajectory is entirely dependent on the timing of contractual milestone payments from partners like Menarini, which obscures the company's true commercial potential. Investors should monitor these figures as discrete capital events rather than indicators of sustainable growth, as the current revenue base provides no insight into future market penetration.
Based on the company's recent income statements, R&D expenditures consistently range between $31 million and $44.8 million per quarter, confirming that the firm's primary capital allocation is directed toward sustaining its extensive Phase 3 clinical trial programs rather than building a commercial infrastructure.
The high concentration of spending in R&D suggests that management is prioritizing the completion of the PREVAIL, BROADWAY, and BROOKLYN trials above all else. This cost structure is expected to remain elevated until clinical data readouts provide a clear path toward regulatory approval and potential commercialization.
According to historical income data, NAMS consistently reports deep operating losses, with quarterly operating margins reaching as low as -2061.9%, illustrating that current licensing revenue is insufficient to offset the substantial cash burn required to fund late-stage clinical development and corporate overhead.
The quality of earnings is currently poor, as net income is heavily influenced by non-operating items and the timing of milestone recognition. The disconnect between reported revenue and operating cash requirements suggests that the firm remains entirely reliant on its existing cash reserves to maintain operations.
While the company maintains a $490 million cash position, the income statement reveals a persistent and significant burn rate that warrants further investigation into the firm's long-term viability should clinical trial results fail to meet the high efficacy thresholds required for competitive market entry.
Short-sellers may focus on the potential for 'indication creep' and the risk that the company's small-molecule CETP inhibitor may struggle to gain formulary placement against established, lower-cost alternatives. The current financial profile suggests that the firm's valuation is almost exclusively tied to binary clinical outcomes rather than operational efficiency.
Quick answers to the most common questions about buying NAMS stock.
For fiscal year 2025, NewAmsterdam Pharma Company N.V. (NAMS) reported total revenue of $22.5M.
NewAmsterdam Pharma Company N.V. (NAMS) reported a net loss of $203.8M for the fiscal year ending 2025.
NewAmsterdam Pharma Company N.V. (NAMS) reported an operating income of $-225.7M, resulting in an operating profit margin of -1002.9%. This margin reflects the operational efficiency of the business before interest and taxes.
NewAmsterdam Pharma Company N.V. (NAMS) generated $22.4M in gross profit for the year, representing a gross profit margin of 99.7%. This demonstrates the company's core pricing power and production efficiency.